Hikma Pharmaceuticals (LON:HIK) Given New GBX 2,500 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. has reduced its price target for Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500, while retaining an "overweight" rating on the stock, suggesting a potential upside of 44.36% from the last closing price.
• Jefferies Financial Group maintained a "buy" rating and a price objective of GBX 2,600 for Hikma Pharmaceuticals, indicating confidence in the company's future performance.
• Hikma Pharmaceuticals' stock opened at GBX 1,731.81 on Friday, showing a significant gap from its 12-month high of GBX 2,360.

Hikma Pharmaceuticals (LON:HIK - Free Report) had its price target lowered by JPMorgan Chase & Co. from GBX 2,600 ($34.97) to GBX 2,500 ($33.62) in a report published on Friday, Marketbeat reports. The firm currently has an overweight rating on the stock.

Separately, Jefferies Financial Group restated a "buy" rating and set a GBX 2,600 ($34.97) price target on shares of Hikma Pharmaceuticals in a research report on Thursday.

Hikma Pharmaceuticals Stock Performance

HIK traded down GBX 20.03 ($0.27) during trading on Friday, hitting GBX 1,729.97 ($23.27). 663,795 shares of the company traded hands, compared to its average volume of 1,040,645. The firm has a market cap of £4.80 billion, a P/E ratio of 16.98, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The stock's fifty day moving average is GBX 2,010.20 and its 200 day moving average is GBX 2,049.65. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. Hikma Pharmaceuticals has a one year low of GBX 1,690 ($22.73) and a one year high of GBX 2,360 ($31.74).

Insider Transactions at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Mazen Darwazah bought 200,000 shares of the business's stock in a transaction on Thursday, August 7th. The stock was purchased at an average price of GBX 1,756 ($23.62) per share, for a total transaction of £3,512,000 ($4,723,604.57). Also, insider Said Darwazah sold 13,863 shares of the stock in a transaction dated Friday, May 30th. The stock was sold at an average price of GBX 2,138 ($28.76), for a total transaction of £296,390.94 ($398,642.82). 30.54% of the stock is owned by company insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.